Legend Biotech (LEGN) Asset Writedowns and Impairment (2020 - 2025)
Legend Biotech's (LEGN) quarterly Asset Writedowns and Impairment came in at $865000.0 in Q3 2025, up 114.64% YoY from $403000.0 in Q3 2024, and up 122.78% on a QoQ basis from -$3.8 million in Q1 2025.
Legend Biotech (LEGN) Asset Writedowns and Impairment (2020 - 2025) Analysis & Trends
Legend Biotech (LEGN) has 5 years of Asset Writedowns and Impairment data on file, last reported at $865000.0 in Q3 2025.
- Quarterly Asset Writedowns and Impairment rose 114.64% year-over-year to $865000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$5.3 million (down 754.17% YoY) and the FY2024 annual result came in at $4.4 million, changed N/A from the prior year.
- Asset Writedowns and Impairment improved to $865000.0 in Q3 2025, from -$3.8 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $1.8 million in Q1 2024 to a low of -$3.8 million in Q1 2025.
- A 4-year average of -$288909.1 and a median of $226000.0 in 2023 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2021 — Asset Writedowns and Impairment jumped 650.0% — and 2025, when it sank 316.16%.
- Tracing LEGN's Asset Writedowns and Impairment over 4 years: stood at $22000.0 in 2021, then slumped by 6209.09% to -$1.3 million in 2023, then slumped by 78.94% to -$2.4 million in 2024, then jumped by 135.97% to $865000.0 in 2025.
- The last three Asset Writedowns and Impairment figures came in at $865000.0 (Q3 2025), -$3.8 million (Q1 2025), and -$2.4 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 865,000.00 |
| Sep 30, 2025 | 865,000.00 |
| Mar 31, 2025 | -3.80 Mn |
| Mar 31, 2025 | -3.80 Mn |
| Dec 31, 2024 | -2.41 Mn |
| Dec 31, 2024 | -2.41 Mn |
| Sep 30, 2024 | 403,000.00 |
| Sep 30, 2024 | 403,000.00 |
| Mar 31, 2024 | 1.76 Mn |
| Mar 31, 2024 | 1.76 Mn |
| Dec 31, 2023 | -1.34 Mn |
| Dec 31, 2023 | -1.34 Mn |
| Sep 30, 2023 | 767,000.00 |
| Sep 30, 2023 | 767,000.00 |
| Jun 30, 2023 | 226,000.00 |
| Jun 30, 2023 | 226,000.00 |
| Mar 31, 2023 | 351,000.00 |
| Mar 31, 2023 | 351,000.00 |
| Dec 31, 2021 | 22,000.00 |
| Dec 31, 2021 | 22,000.00 |